Program
trastuzumab brengitecan
Also written as “BL-M07D1”, “T-Bren, Dose level 1” and “T-bren, Dose level 2”.
In Sichuan Biokin Pharmaceutical’s pipeline, HER2 ADC
. Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Urinary Bladder Neoplasms · Endometrial Neoplasms · Colorectal Neoplasms, led by Sichuan Biokin Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Biokin Pharmaceutical | 2121 open or running | phase 3since Mar 12, 2024 | Jul 14, 2022 | Dec 2026phase 2 · NCT06114511 |
- Named in Sichuan Biokin Pharmaceutical’s own pipeline as
T-Bren (BL-M07D1, HER2 ADC)
, phase 3, as of Nov 16, 2026 (source).
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 5 earlier studies, Jul 14, 2022 to Nov 9, 2023.
- Aug 6, 2023Named trastuzumab brengitecanINNProposed as its International Nonproprietary Name in WHO's List 129
- Feb 22, 2024Phase 1 study in Endometrial NeoplasmsNCT06293898 · 280 planned · United States
- Mar 12, 2024Phase 3 study in HER2-positive Breast CancerNCT06316531 · 274 enrolled · China
- May 16, 20242 phase 2 studiesNCT06423885, NCT06445400
- Feb 12, 2025Phase 3 study in HER2-positive Breast CancerNCT06830889 · 1,450 planned · China
- Mar 18, 2025Phase 3 study in HER2-positive Breast CancerNCT06891833 · 985 planned · China
- Apr 27, 2025Phase 3 study in HER2-low Breast CancerNCT06957886 · 566 planned · China
- Aug 26, 2025Phase 3 study in Gastric AdenocarcinomaNCT07152405 · 490 planned · China
- Sep 11, 2025Phase 3 study in Non-squamous Non-small Cell Lung CancerNCT07178795 · 440 planned · China
- Nov 24, 2025Phase 2 study in Non-squamous Non-small Cell Lung CancerNCT07264816 · 80 planned · China
- Apr 2, 20262 phase 3 studiesNCT07518173, NCT07545460
- May 19, 2026Phase 3 study in Biliary Tract NeoplasmsNCT07606599 · 398 planned · China
- Jun 25, 2026Phase 2 study in Breast NeoplasmsNCT07678957 · 120 planned · China
- Jul 23, 2026Phase 3 study in Colorectal NeoplasmsNCT07730489 · 130 planned · China
- Oct 6, 2026Phase 3 study in Urinary Bladder NeoplasmsNCT07869836 · 520 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06114511
- Dec 2026Primary completion: phase 2 study in Her2-positive/Low-expression Urinary and Digestive Tract TumorsNCT06031584
- Dec 2026Primary completion: phase 1 study in Locally Advanced or Metastatic Digestive Tract TumorsNCT05631964
- Dec 2026Primary completion: phase 1 study in Breast NeoplasmsNCT05461768
TargetBeta
“HER2 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07869836Urinary Bladder Neoplasms · United States | 3 | Recruiting | Dec 2028 | 520 |
| NCT07730489Colorectal Neoplasms · China | 3 | Not yet recruiting | Dec 2027 | 130 |
| NCT07678957Breast Neoplasms · China | 2 | Recruiting | Dec 2028 | 120 |
| NCT07606599Biliary Tract Neoplasms · China | 3 | Recruiting | Dec 2028 | 398 |
| NCT07545460Carcinoma, Ovarian Epithelial · China | 3 | Not yet recruiting | Dec 2028 | 404 |
| NCT07518173HER2-positive Breast Cancer · China | 3 | Recruiting | Dec 2029 | 596 |
| NCT07264816Non-squamous Non-small Cell Lung Cancer · China | 2 | Recruiting | Dec 2027 | 80 |
| NCT07178795Non-squamous Non-small Cell Lung Cancer · China | 3 | Recruiting | Dec 2027 | 440 |
| NCT07152405Gastric Adenocarcinoma · China | 3 | Recruiting | Jun 2027 | 490 |
| NCT06957886HER2-low Breast Cancer · China | 3 | Recruiting | May 2027 | 566 |
| NCT06891833HER2-positive Breast Cancer · China | 3 | Recruiting | Dec 2028 | 985 |
| NCT06830889HER2-positive Breast Cancer · China | 3 | Recruiting | Oct 2031 | 1,450 |
| NCT06445400HER2-positive Breast Cancer · China | 2 | Active, not recruiting | Jul 21, 2025 | 83 |
| NCT06423885HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma · China | 2 | Active, not recruiting | Oct 2026 | 64 |
| NCT06316531HER2-positive Breast Cancer · China | 3 | Active, not recruiting | Oct 2026 | 274 |
| NCT06293898Endometrial Neoplasms · United States | 1 | Recruiting | Dec 15, 2028 | 280 |
| NCT06131450Gynecological Malignancies · China | 2 | Recruiting | Jan 2027 | 158 |
| NCT06114511Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Dec 2026 | 78 |
| NCT06031584Her2-positive/Low-expression Urinary and Digestive Tract Tumors · China | 2 | Recruiting | Dec 2026 | 42 |
| NCT05631964Locally Advanced or Metastatic Digestive Tract Tumors · China | 1 | Recruiting | Dec 2026 | 26 |
| NCT05461768Breast Neoplasms · China | 1 | Recruiting | Dec 2026 | 348 |
How it is read
Names in the registry
- “BL-M07D1”, 20 entries
- “T-Bren, Dose level 1”, 1 entry
- “T-bren, Dose level 2”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 8 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Urinary Bladder Neoplasms, 1 study
- Endometrial Neoplasms, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.